An open-label, non-randomized study to evaluate the effect of PEGASYS [peginterferon alfa-2a] on HBV-DNA [hepatitis B virus-DNA] in patients with HBeAG-negative [hepatitis B e antigen-negative] chronic hepatitis B infection.

Trial Profile

An open-label, non-randomized study to evaluate the effect of PEGASYS [peginterferon alfa-2a] on HBV-DNA [hepatitis B virus-DNA] in patients with HBeAG-negative [hepatitis B e antigen-negative] chronic hepatitis B infection.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2015

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 26 Jun 2007 Status changed from in progress
    • 08 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top